SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aimei Health Technology Co., Ltd. is a blank check company, which engages in entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on April 27, 2023 and is headquartered in New York, NY.

Aimei Health Technology Co Ltd

Aimei Health Technology ($AFJK) is trending due to a massive intraday surge, reportedly driven by social media and chat room momentum. Traders are discussing the potential for continued gains, while also pointing out the risks associated with the stock's volatility and low float. Some users are comparing it to other high-flying stocks, while others suggest caution due to its two-employee structure and potential for a pump-and-dump.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir $PLTR is trending amid news of a $448M Navy contract for its ShipOS AI platform, intended to modernize submarine maintenance. Community discussions revolve around the potential impact on revenue and global expansion, with some questioning the valuation and others remaining strongly bullish. Broader conversations touch on Palantir's growing presence in corporate America and the implications of government contracts.

Oriental Culture Holding Ltd. operates as a holding company, which is engaged in providing collectibles and artwork e-commerce services through its subsidiaries. The firm facilitates trading by individual customers of all kinds of collectibles, artwork, and certain commodities on its online platform owned by its subsidiary in Hong Kong, namely the China International Assets and Equity of Artworks Exchange Limited. It provides services including investor education, market information, customer support, and technology infrastructure. The company was founded in March 2018 and is headquartered in Hong Kong.

Oriental Culture Holding Ltd

Oriental Culture Holding is trending due to a massive surge in price and trading volume, with community members citing early alerts from specific users and comparing it to other recent high-percentage runners. Traders are actively discussing entry and exit points, as well as overnight price action, while also speculating about the company's fundamentals and potential for further gains. The stock's movement is also drawing attention as part of a broader trend involving Hong Kong-based stocks experiencing significant volatility.

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Enveric Biosciences Inc

Enveric Biosciences is trending due to recent attention on its low float and potential for a short squeeze, with some traders drawing comparisons to other high-momentum stocks. Community members are discussing the company's intellectual property and ongoing patent litigation related to AbbVie's acquisition, speculating on a possible settlement. The stock's volatile history, including reverse splits and public offerings, is also a key point of discussion among investors.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices surge to new highs, driven by increasing industrial demand, supply constraints, and renewed interest in precious metals amid economic uncertainty. The community is actively discussing potential price targets and the possibility of a silver squeeze, with many highlighting the metal's growing importance in green technologies and electronics. Some traders are debating whether this rally is sustainable or if a pullback is imminent.

Greenwave Technology Solutions, Inc. is an emerging growth company, which engages in recycling ferrous metal. It also recycles nonferrous metals including aluminum, copper, stainless steel, nickel, brass, titanium, lead, alloys, and mixed metal products. The company was founded on April 26, 2013 and is headquartered in Chesapeake, VA.

Greenwave Technology Solutions Inc

GWAV is trending as traders discuss its volatile price action and potential for a short squeeze, with community members pointing to its low float and high short interest. Some are skeptical, citing past reverse splits and delayed filings, while others see upside in the metal recycling sector. Discussions also mention potential connections to rare earth elements and sympathy plays with other trending tickers.

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Boston, MA.

Vor Biopharma Inc

VOR is trending as community members discuss its potential after JP Morgan initiated coverage with an overweight rating and a $43 price target. Some traders believe VOR is primed for a short squeeze, while others point to high trading volume and potential catalysts from its pipeline. Discussions also focus on the company's recent acquisition of telitacicept and upcoming clinical milestones.

Horizon Space Acquisition I Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on June 14, 2022 and is headquartered in New York, NY.

Horizon Space Acquisition I Corp

Horizon Space Acquisition I Corp (HSPO) is trending due to a massive volume spike and price surge, driven by its announcement of voluntary delisting from the Nasdaq. The community is actively discussing potential short squeezes and comparing it to other high-flying, low-float stocks, while also cautioning about the risks associated with a delisting company.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment ($AVAV) is trending amid mixed reactions to its latest earnings report, which featured a revenue beat but an EPS miss, alongside raised full-year earnings guidance. The community is actively debating the company's growth prospects, margin performance, and the potential impact of defense spending trends. Bullish sentiment is fueled by strong revenue growth and significant contract wins, while bears point to margin concerns and government guidance.

AlphaVest Acquisition Corp. is a blank check company, which engages in effecting a merger, stock exchange, asset acquisition, stock purchase, and reorganization or similar business combination. The company was founded on January 14, 2022 and is headquartered in New York, NY.

AlphaVest Acquisition Corp

ATMV is trending due to the closing of its business combination with AMC Robotics Corporation, with the combined company expected to trade under the ticker AMCI. Community chatter highlights the potential for significant price movement, drawing comparisons to other high-flying SPACs and robotic stocks. Some traders are discussing the low float and merger news, while others point to the potential for a short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Carisma Announces Delisting from Nasdaq and SEC Deregistration

Carisma Announces Delisting from Nasdaq and SEC Deregistration Carisma Announces Delisting from Nasdaq and SEC Deregistration PR Newswire PHILADELPHIA, Dec. 5, 2025 PHILADELPHIA, Dec. 5, 2025...

JPM downgrades Avis Budget after stock rally on recall, tariff impact

Investing.com -- JP Morgan downgraded  Avis Budget  (NASDAQ:CAR) Group to Neutral from Overweight, saying the stock’s sharp rally since March has outpaced the underlying earnings outlook, while near-term pressures from safety recalls and fading tariff tailwinds weigh on estimates.

These companies are most likely to surprise in real estate H1 earnings season

Investing.com -- Bernstein expects a mixed but potentially positive first-half earnings season for the European real estate sector, highlighting nine companies that could raise their guidance.

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference PR...

Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference...

Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline

Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline PR Newswire PHILADELPHIA, Dec. 9...

Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting 2024

Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting 2024 Carisma Therapeutics Presents Promising New...

Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights PR...

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024 Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for...

Carisma Therapeutics Announces Changes to its Board of Directors

Carisma Therapeutics Announces Changes to its Board of Directors Carisma Therapeutics Announces Changes to its Board of Directors PR Newswire PHILADELPHIA, Oct. 30, 2024 Appointment of Sohanya Cheng...

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in April 2016 and is headquartered in Philadelphia, PA.

CARM
Carisma Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CARM News

CARMCarisma Therapeutics Inc